![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1456, 2004-01, pp. : 6-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Biological agents promising in plaque psoriasis
Inpharma, Vol. 1, Iss. 1625, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol a strong contender in chronic plaque psoriasis
Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Methotrexate vs cyclosporin in chronic plaque psoriasis
Inpharma, Vol. 1, Iss. 1401, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Etanercept, efalizumab repair QOL in chronic plaque psoriasis
Inpharma, Vol. 1, Iss. 1456, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Etanercept, efalizumab repair QOL in chronic plaque psoriasis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 463, 2004-01 ,pp. :